Assetmark Inc. Sells 947 Shares of Fresenius Medical Care AG (NYSE:FMS)

Assetmark Inc. lowered its position in Fresenius Medical Care AG (NYSE:FMS) by 28.0% during the third quarter, according to its most recent filing with the SEC. The firm owned 2,433 shares of the company’s stock after selling 947 shares during the period. Assetmark Inc.’s holdings in Fresenius Medical Care were worth $52,000 as of its most recent filing with the SEC.

A number of other institutional investors have also bought and sold shares of the company. Allworth Financial LP boosted its stake in Fresenius Medical Care by 53.1% during the third quarter. Allworth Financial LP now owns 1,675 shares of the company’s stock worth $36,000 after acquiring an additional 581 shares in the last quarter. GAMMA Investing LLC boosted its holdings in shares of Fresenius Medical Care by 50.4% in the 3rd quarter. GAMMA Investing LLC now owns 4,998 shares of the company’s stock worth $106,000 after buying an additional 1,675 shares during the last quarter. ORG Wealth Partners LLC bought a new position in Fresenius Medical Care during the third quarter valued at $112,000. Signaturefd LLC boosted its position in Fresenius Medical Care by 8.4% during the second quarter. Signaturefd LLC now owns 8,713 shares of the company’s stock worth $166,000 after purchasing an additional 672 shares during the period. Finally, Kimelman & Baird LLC bought a new stake in shares of Fresenius Medical Care during the 2nd quarter valued at $186,000. Institutional investors own 8.25% of the company’s stock.

Fresenius Medical Care Price Performance

Shares of Fresenius Medical Care stock opened at $22.14 on Tuesday. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.37 and a quick ratio of 1.02. Fresenius Medical Care AG has a one year low of $17.93 and a one year high of $22.76. The business’s 50 day simple moving average is $20.70 and its two-hundred day simple moving average is $20.24. The stock has a market capitalization of $12.99 billion, a P/E ratio of 18.29, a price-to-earnings-growth ratio of 1.02 and a beta of 0.91.

Wall Street Analyst Weigh In

Several analysts have weighed in on FMS shares. Berenberg Bank assumed coverage on Fresenius Medical Care in a report on Wednesday, November 6th. They issued a “buy” rating and a $25.60 price target on the stock. StockNews.com began coverage on shares of Fresenius Medical Care in a report on Saturday, November 9th. They issued a “strong-buy” rating for the company. Finally, Truist Financial increased their target price on shares of Fresenius Medical Care from $22.00 to $23.00 and gave the company a “hold” rating in a report on Monday, October 7th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, one has issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $24.30.

Fresenius Medical Care Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.